PL3328361T3 - Cząstki nanożywicy zawierające lek - Google Patents

Cząstki nanożywicy zawierające lek

Info

Publication number
PL3328361T3
PL3328361T3 PL16829974T PL16829974T PL3328361T3 PL 3328361 T3 PL3328361 T3 PL 3328361T3 PL 16829974 T PL16829974 T PL 16829974T PL 16829974 T PL16829974 T PL 16829974T PL 3328361 T3 PL3328361 T3 PL 3328361T3
Authority
PL
Poland
Prior art keywords
drug loaded
nanoresin particles
loaded nanoresin
particles
drug
Prior art date
Application number
PL16829974T
Other languages
English (en)
Inventor
Ajay Jaysingh Khopade
Arindam Halder
Shivam Umeshkumar UPADHYAY
Original Assignee
Sun Pharma Advanced Research Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Ltd filed Critical Sun Pharma Advanced Research Company Ltd
Publication of PL3328361T3 publication Critical patent/PL3328361T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16829974T 2015-07-27 2016-07-27 Cząstki nanożywicy zawierające lek PL3328361T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2841MU2015 2015-07-27
PCT/IN2016/050253 WO2017017699A1 (en) 2015-07-27 2016-07-27 Drug loaded nanoresin particles
EP16829974.1A EP3328361B1 (en) 2015-07-27 2016-07-27 Drug loaded nanoresin particles

Publications (1)

Publication Number Publication Date
PL3328361T3 true PL3328361T3 (pl) 2021-12-13

Family

ID=57884335

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16829974T PL3328361T3 (pl) 2015-07-27 2016-07-27 Cząstki nanożywicy zawierające lek

Country Status (6)

Country Link
US (2) US20190008772A1 (pl)
EP (2) EP3328361B1 (pl)
JP (2) JP6856620B2 (pl)
ES (1) ES2891344T3 (pl)
PL (1) PL3328361T3 (pl)
WO (1) WO2017017699A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3328361T3 (pl) * 2015-07-27 2021-12-13 Sun Pharma Advanced Research Company Ltd Cząstki nanożywicy zawierające lek
AU2019312592A1 (en) 2018-07-31 2021-02-18 Microbion Corporation Bismuth-thiol compositions and methods for treating wounds
FR3108841B1 (fr) * 2020-04-06 2023-11-03 Algotherapeutix Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline
CA3204243A1 (en) * 2021-01-13 2022-07-21 Ajay Jaysingh Khopade Method of reducing elevated intraocular pressure
US20230330100A1 (en) * 2022-02-17 2023-10-19 Woolsey Pharmaceuticals, Inc. Taste-masking oral formulations of fasudil
US11944633B2 (en) 2022-02-17 2024-04-02 Woolsey Pharmaceuticals, Inc. Oral formulations of fasudil with ion exchange resin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA161597A (en) * 1915-03-02 1915-03-30 John R. Van Wormer Box
CA1161597A (en) 1978-09-19 1984-01-31 Rohm And Haas Company Emulsion copolymer cation exchange resins and ion exchange process therewith
US4380590A (en) 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
EP1706095B1 (en) * 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20090098192A1 (en) * 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
JP5497761B2 (ja) 2008-08-05 2014-05-21 マンカインド コーポレ−ション 改良型粉体ディスペンサモジュールおよび粉体ディスペンサアセンブリ
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8142976B2 (en) * 2009-12-03 2012-03-27 Eastman Kodak Company Method for preparing multiple emulsion and porous polymer particles therefrom
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
JP5808214B2 (ja) * 2011-09-30 2015-11-10 株式会社トクヤマ 貼付剤
AU2015274377B2 (en) * 2014-06-13 2020-07-23 United Therapeutics Corporation Treprostinil formulations
PL3179982T3 (pl) * 2014-07-28 2023-09-25 Sun Pharma Advanced Research Company Ltd Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku
PL3328361T3 (pl) 2015-07-27 2021-12-13 Sun Pharma Advanced Research Company Ltd Cząstki nanożywicy zawierające lek

Also Published As

Publication number Publication date
WO2017017699A1 (en) 2017-02-02
US20200170951A1 (en) 2020-06-04
US20190008772A1 (en) 2019-01-10
EP3328361A1 (en) 2018-06-06
JP2021105009A (ja) 2021-07-26
JP6856620B2 (ja) 2021-04-07
JP2018525370A (ja) 2018-09-06
EP3943072A1 (en) 2022-01-26
EP3328361A4 (en) 2019-04-10
JP7236484B2 (ja) 2023-03-09
US11559487B2 (en) 2023-01-24
EP3328361B1 (en) 2021-09-15
ES2891344T3 (es) 2022-01-27

Similar Documents

Publication Publication Date Title
IL270954A (en) Pharmaceutical compounds
IL258213B (en) Pharmaceutical compounds
GB201414730D0 (en) Pharmaceutical compound
GB201506658D0 (en) Pharmaceutical compounds
IL258246A (en) Pharmaceutical compounds
GB201504675D0 (en) Pharmaceutical compounds
GB201506660D0 (en) Pharmaceutical compounds
GB201404922D0 (en) Pharmaceutical compounds
GB201519352D0 (en) Pharmaceutical compounds
PL3328361T3 (pl) Cząstki nanożywicy zawierające lek
GB201506933D0 (en) Pharmaceutical compounds
GB201502567D0 (en) Pharmaceutical compounds
GB201416513D0 (en) Pharmaceutical compounds
GB201402783D0 (en) Powder delivery means
GB201417707D0 (en) Pharmaceutical compounds
GB201420311D0 (en) Pharmaceutical processing
IL250160A0 (en) medicinal substance
ZA201708393B (en) Large particles
GB201608923D0 (en) Drug delivery particles
GB201517451D0 (en) Pharmaceutical compounds
GB201503733D0 (en) New drug application
GB201503731D0 (en) New drug application
GB201508022D0 (en) Pharmaceutical compounds
GB201419570D0 (en) Pharmaceutical compound
GB201416968D0 (en) Pharmaceutical compounds